llumina on Thursday forecast core business revenue to be nearly flat in the coming year compared to 2023 amid subdued demand for its genetic testing tools and diagnostics products. The San Diego-based ...

SHENZHEN, China, Feb. 8, 2024 /PRNewswire/ -- MGI Tech, a company committed to building core tools and technology to lead life science, today announced its nomination as a finalist for the 2024 Edison ...

Bangalore (Reuters) - Companies that make the gene-sequencing devices used in scientific research face a tough few years as potential cuts to the U.S. federal budget squeeze funding to its main ...

Two University of Wisconsin researchers Edgar Spalding and Takeshi Yoshihara recently published a study concluding that there ...

Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Request A Quote Download PDF Copy Request A Quote Download ...

Illumina (NASDAQ:ILMN) on Monday lowered its adjusted profit outlook and cut spending costs for 2025 as the company grapples with a Chinese ban on its gene sequencers. Illumina now expects fiscal 2025 ...

Illumina Inc. introduced a new line of gene-sequencing machines that the company says can more than double capacity versus prior sequencers, while reducing the cost per genome. The rollout, which ...

Most biopharma players need access to gene sequencing services. Illumina is facing a handful of headwinds, but it's still the market leader. Bionano Genomics is unproven but expanding quickly. So ...

Elucidating the relationship between the sequences of non-coding regulatory elements and their target genes is key to understanding gene regulation and its variation between plant species and ecotypes ...

SANTA CLARA, CA--(Marketwire - Oct 31, 2012) - NVIDIA® Tesla® GPU accelerators are enabling Life Technologies Corporation's new Ion Proton™ System to accelerate primary genome-sequence analysis-- the ...

A study has found that more than 41,000 missing RNA transcripts and hundreds of potential new genes have been overlooked due ...